# Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

> **NCT01606735** · PHASE2 · COMPLETED · sponsor: **ICON Bioscience Inc** · enrollment: 172 (actual)

## Conditions studied

- Inflammation Associated With Cataract Surgery

## Interventions

- **DRUG:** IBI-10090

## Key facts

- **NCT ID:** NCT01606735
- **Lead sponsor:** ICON Bioscience Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2014-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606735, "Efficacy and Safety of IBI-10090 in Ocular Surgery Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01606735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*